9 completed. 9 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 9 | Completed 9 |
| Phase 2 | 1 | Completed 1 |
Follow Relapsing Remitting Multiple Sclerosis: new trials by email Literature Review of Relapsing Remitting Multiple Sclerosis trials Research Report on Relapsing Remitting Multiple Sclerosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2 ALKS 8700, Dimethyl Fumarate - Relapsing Remitting Multiple Sclerosis | Phase 3 | Completed | Biogen | 506 | 2017-03-15 | 2020-07-14 |
| Vitamin D Supplementation in Multiple Sclerosis Vitamin D3 - Relapsing Remitting Multiple Sclerosis | Phase 3 | Completed | Johns Hopkins University | 172 | 2012-03-01 | 2022-09-28 |
| Advanced MRI Measures of Repair in Alemtuzumab Treated Patients MabCampath-1h - Relapsing Remitting Multiple Sclerosis | Phase 3 | Completed | University of British Columbia | 27 | 2011-03-01 | 2018-10-16 |
| A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo Glatiramer acetate (GA), Placebo - Relapsing Remitting Multiple Sclerosis | Phase 3 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 1404 | 2010-06-22 | 2021-12-09 |
| Safety of New Formulation of Glatiramer Acetate Glatiramer Acetate, Experimental Glatiramer Acetate - Relapsing Remitting Multiple Sclerosis | Phase 3 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 147 | 2009-07-01 | 2017-03-14 |
| A Study for Patients With Relapsing Remitting Multiple Sclerosis dirucotide, placebo - Relapsing Remitting Multiple Sclerosis | Phase 2 / Phase 3 | Completed | Eli Lilly and Company | 218 | 2006-11-01 | 2010-09-09 |
| Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With Two Doses of Glatiramer Acetate (GA). Glatiramer Acetate (GA) 40 mg, glatiramer acetate 20 mg - Relapsing Remitting Multiple Sclerosis | Phase 3 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 1155 | 2006-08-01 | 2011-10-10 |
| Simvastatin in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Using Avonex Compared to Placebo simvastatin, placebo - Relapsing Remitting Multiple Sclerosis | Phase 3 | Completed | Tehran University of Medical Sciences | 80 | 2005-04-01 | 2010-07-30 |
| Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRx Interferon beta 1-a, glatiramer acetate, placebo - Relapsing Remitting Multiple Sclerosis | Phase 3 | Completed | Fred Lublin | 1008 | 2005-01-01 | 2014-04-03 |
Multiple Sclerosis, Relapsing-Remitting (9) · Multiple Sclerosis (4) · Autoimmune Diseases (2) · Autoimmune Diseases of the Nervous System (1) · Demyelinating Autoimmune Diseases, CNS (1) · Demyelinating Diseases (1) · Immune System Diseases (1) · Nervous System Diseases (1)
Autoimmune Diseases of the Nervous System (8) · Demyelinating Autoimmune Diseases, CNS (8) · Demyelinating Diseases (8) · Immune System Diseases (8) · Nervous System Diseases (8) · Autoimmune Diseases (7) · Multiple Sclerosis (5) · Brain Diseases (1) · Central Nervous System Diseases (1) · Leukoencephalopathies (1)
Glatiramer Acetate (4) · Alemtuzumab (1) · Cholecalciferol (1) · Dimethyl Fumarate (1) · Interferon beta-1a (1) · MBP-8298 (1) · Simvastatin (1)
Teva Branded Pharmaceutical Products R&D, Inc. (3) · Biogen (1) · Eli Lilly and Company (1) · Fred Lublin (1) · Johns Hopkins University (1) · Tehran University of Medical Sciences (1) · University of British Columbia (1)
United States (4) · Poland (3) · Bulgaria (2) · Canada (2) · Germany (2) · Russia (2) · Ukraine (2) · Croatia (1) · Czechia (1) · Estonia (1) · Georgia (1) · Hungary (1) · Iran (1) · Israel (1) · Italy (1)
Anthony Traboulsee, MD (1) · Chen Duksin, MD (1) · Ellen M Mowry, MD, MCR (1) · Fred Lublin, MD (1) · Giancarlo Comi, Prof (1) · Mansooreh Togha, MD (1) · Tom Smith, MD (1)
PMID 20488825, PMID 23424159, PMID 24686106, PMID 25311447, PMID 27503905, PMID 31289819, PMID 31953790, PMID 32539719, PMID 32554770, PMID 33796143, PMID 34376508, PMID 34433679, PMID 34695274, PMID 34759712, PMID 34927308, PMID 36382118, PMID 37119208, PMID 37125397, PMID 37830451, PMID 38878121
2009 (1), 2017 (1), U01NS045719 (1)